Tarsier Pharma's planned NYSE American IPO under ticker TARX, filed in April 2026 with terms updated in May and July for 5.56 million shares at $8–$10 implying roughly $50–60 million gross proceeds, has not closed as of early August 2026. This underpins the 98.6% market-implied probability of no IPO before September amid the company's clinical-stage status, ongoing Phase 3 Tarsier-04 trial preparations for non-infectious uveitis, net losses of $5.07 million over the prior twelve months, and zero revenue. Biotech equity issuance windows and regulatory timelines for ocular candidates continue to influence timing. A positive clinical catalyst or improved capital markets sentiment could accelerate closing and shift implied market cap probabilities, though current filings and trial schedules point to further delays.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertTarsier Pharma IPO Closing Marktkapitalisierung
Tarsier Pharma IPO Closing Marktkapitalisierung
Kein Börsengang vor September 2026 98.4%
400 Mio. $ – 450 Mio. $ 3.1%
350 Mio. $–400 Mio. $ 1.8%
<250 Mio. $ 1.6%
$14,952 Vol.
$14,952 Vol.
9. Juli 2026
<250 Mio. $
2%
250 Mio. $–300 Mio. $
2%
300 Mio. $ - 350 Mio. $
<1%
350 Mio. $–400 Mio. $
2%
400 Mio. $ – 450 Mio. $
3%
>450 Mio. $
<1%
Kein Börsengang vor September 2026
98%
Kein Börsengang vor September 2026 98.4%
400 Mio. $ – 450 Mio. $ 3.1%
350 Mio. $–400 Mio. $ 1.8%
<250 Mio. $ 1.6%
$14,952 Vol.
$14,952 Vol.
9. Juli 2026
<250 Mio. $
$907 Vol.
2%
250 Mio. $–300 Mio. $
$839 Vol.
2%
300 Mio. $ - 350 Mio. $
$561 Vol.
<1%
350 Mio. $–400 Mio. $
$561 Vol.
2%
400 Mio. $ – 450 Mio. $
$349 Vol.
3%
>450 Mio. $
$680 Vol.
<1%
Kein Börsengang vor September 2026
$11,055 Vol.
98%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned NYSE American IPO under ticker TARX, filed in April 2026 with terms updated in May and July for 5.56 million shares at $8–$10 implying roughly $50–60 million gross proceeds, has not closed as of early August 2026. This underpins the 98.6% market-implied probability of no IPO before September amid the company's clinical-stage status, ongoing Phase 3 Tarsier-04 trial preparations for non-infectious uveitis, net losses of $5.07 million over the prior twelve months, and zero revenue. Biotech equity issuance windows and regulatory timelines for ocular candidates continue to influence timing. A positive clinical catalyst or improved capital markets sentiment could accelerate closing and shift implied market cap probabilities, though current filings and trial schedules point to further delays.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Markt eröffnet: Jul 7, 2026, 9:12 AM ET
Volumen
$14,952Enddatum
9. Juli 2026Markt eröffnet
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned NYSE American IPO under ticker TARX, filed in April 2026 with terms updated in May and July for 5.56 million shares at $8–$10 implying roughly $50–60 million gross proceeds, has not closed as of early August 2026. This underpins the 98.6% market-implied probability of no IPO before September amid the company's clinical-stage status, ongoing Phase 3 Tarsier-04 trial preparations for non-infectious uveitis, net losses of $5.07 million over the prior twelve months, and zero revenue. Biotech equity issuance windows and regulatory timelines for ocular candidates continue to influence timing. A positive clinical catalyst or improved capital markets sentiment could accelerate closing and shift implied market cap probabilities, though current filings and trial schedules point to further delays.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volumen
$14,952Enddatum
9. Juli 2026Markt eröffnet
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's planned NYSE American IPO under ticker TARX, filed in April 2026 with terms updated in May and July for 5.56 million shares at $8–$10 implying roughly $50–60 million gross proceeds, has not closed as of early August 2026. This underpins the 98.6% market-implied probability of no IPO before September amid the company's clinical-stage status, ongoing Phase 3 Tarsier-04 trial preparations for non-infectious uveitis, net losses of $5.07 million over the prior twelve months, and zero revenue. Biotech equity issuance windows and regulatory timelines for ocular candidates continue to influence timing. A positive clinical catalyst or improved capital markets sentiment could accelerate closing and shift implied market cap probabilities, though current filings and trial schedules point to further delays.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · AktualisiertVerwandte
Wird die Marktkapitalisierung von Latigo Biotherapeutics am Tag des Börsengangs zum Handelsschluss zwischen 1,15 Mrd. $ und 1,3 Mrd. $ liegen?
73%
Ja
Wird CopperTech Metals vor September 2026 nicht an die Börse gehen?
99%
Ja
Wird Discords Marktkapitalisierung am Börsenschlusstag des Börsengangs bis zum 31. Dezember 2027 zwischen 8 und 11 Milliarden US-Dollar liegen?
24%
Ja
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen